Evaluating a clinical care pathway for the screening, diagnosis and treatment of fatty liver disease among primary care patients

Not Applicable

• Conditions: on-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH); Digestive System; Other specified inflammatory liver diseases

• Registration Number: ISRCTN46342829
• Lead Sponsor: niversity of Crete

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-05-27
• Last Update Posted: 6 March 2023
• Study Completion: 2023-03-15

Recruitment & Eligibility

• Status: Ongoing
• Sex: All
• Target Recruitment: 220

Inclusion Criteria

Current inclusion criteria as of 15/02/2023:
1. Metabolic dysfunction: overweight/obesity OR type 2 diabetes OR metabolic syndrome (MetS)
OR
2. Liver dysfunction: raised alanine aminotransferase (ALT) OR raised aspartate aminotransferase (AST)
OR
3. NAFLD: an ultrasonographic fatty liver indicator (US-FLI) >60 AND no other causes of liver disease AND no alcohol excess
OR
4. Cardiovascular disease (CVD): any diagnosis or medication for CVD

Previous inclusion criteria:
1. Registered as a patient in the practice of the participating GP
2. Age >=50 years
3. One or more of the following conditions:
3.1. Obesity (BMI>30)
3.2. Type 2 diabetes (T2DM)
3.3. Metabolic syndrome (MetS)

Exclusion Criteria

1. Not registered in the selected GPs practice
2. Unwillingness or inability to provide signed informed consent and complete study procedures due to cognitive impairment, dementia and/or terminal illness

Study & Design

• Study Type: Interventional
• Study Design: Not specified